aTyr Pharma Inc.

258 articles about aTyr Pharma Inc.

• aTyr Pharma to Present Poster at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II

  5/20/2020

  Poster details data from aTyr’s pre-clinical, domain specific Neuropilin-2 (NRP2) antibody program highlighting therapeutic potential in triple-negative breast cancer

• aTyr Pharma Announces First Quarter 2020 Results and Provides Corporate Update on ATYR1923 Clinical Trials in Pulmonary Sarcoidosis and COVID-19Company to host conference call and webcast today, May 12, at 5:00 p.m. EDT / 2:00 p.m. PDT

  5/12/2020

  aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, announced first quarter results and provided a corporate update.

• aTyr Pharma to Webcast Conference Call Reporting First Quarter 2020 Financial ResultsManagement to host conference call and webcast on May 12th at 5:00 pm EDT / 2:00 pm PDT

  5/6/2020

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report first quarter 2020 financial results and provide a corporate update after the market close on Tuesday, May 12, 2020. Conference Call and Webcast Details: Tuesday, May 12th @ 5:00 p.m. EDT / 2:00 p.m. PDT Domestic:  844-358-9116 International:  209-90

• aTyr Pharma Announces Publication of Two Abstracts in American Journal of Respiratory and Critical Care Medicine

  5/5/2020

  Abstracts originally accepted for presentation at the 2020 American Thoracic Society (ATS) International Conference Findings confirm that aTyr’s lead clinical candidate, ATYR1923, selectively binds to Neuropilin-2 (NRP2), a unique target expressed on key immune cells in inflammatory conditions SAN DIEGO, May 05, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological

• 

  Clinical Catch-Up: April 20-24

  4/27/2020

  Despite the domination of the news cycle by the COVID-19 pandemic, quite a number of biopharma companies reported on non-COVID-19 clinical trials last week, although there remains plenty of ongoing trial news related to the pandemic. Here’s a look.
• 

  Biopharma Update on the Novel Coronavirus: April 21

  4/21/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 21, 2020.

• aTyr Pharma Announces Phase 2 Study of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications Following FDA Acceptance of IND Application

  4/21/2020

  aTyr Pharma, Inc. announced that the U.S. Food and Drug Administration has accepted its Investigational New Drug application to evaluate its lead therapeutic candidate, ATYR1923, in a Phase 2 study in COVID-19 patients with severe respiratory complications..

• aTyr Pharma Announces Fourth Quarter and Full Year 2019 Results and Provides Corporate Update

  3/26/2020

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced fourth quarter and full year 2019 results and provided a corporate update.

• aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Announce Government Grant to Fund Bispecific Antibody Development Platform

  3/24/2020

  Grant awarded by the Hong Kong Government's Innovation and Technology Commission under the Partnership Research Program Two-year project will initially focus on development of new bi-specific antibodies targeting NRP2 SAN DIEGO, March 24, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the company’s Hong Kong subsidiary, Pangu Bi

• aTyr Pharma to Announce Fourth Quarter and Full Year End 2019 Financial Results on March 26thManagement to host conference call and webcast at 5:00 pm EST / 2:00 pm PST

  3/19/2020

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report fourth quarter and full year 2020 financial results after the market close on Thursday, March 26, 2020.

• Leading Cancer Researcher Dr. Arthur M. Mercurio Joins aTyr as Scientific AdvisorDr. Mercurio to advise company on the development of novel antibody therapeutics targeting neuropilin-2 (NRP2) for cancer

  3/17/2020

  aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, announced the appointment of Arthur M. Mercurio, Ph.D. as a scientific advisor to the company.

• aTyr Pharma Announces Exercise and Closing of Over-Allotment Option in Public Offering

  3/10/2020

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced the underwriters of its previously announced public offering of common stock have fully exercised their over-allotment option resulting in the issuance of an additional 635,294 shares of common stock. The option was granted in connection with the public offering of 4,235,

• aTyr Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting

  3/3/2020

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the company will present an abstract in a poster session at the upcoming AACR Annual Meeting, which is being held April 24 – 29, 2020 at the San Diego Convention Center.

• aTyr Pharma Announces Publication in the Journal Cellular and Molecular Immunology

  2/27/2020

  Paper highlights the essential role thathistidyl tRNA synthetase (HARS) plays in immune responses in a broad range of inflammatory disease states

• aTyr Pharma Announces Pricing of $18 million Underwritten Public Offering

  2/6/2020

  SAN DIEGO, Feb. 06, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced the pricing of an underwritten public offering of 4,235,294 shares of its common stock at a price to the public of $4.25 per share. The offering is expected to close on or about February 10, 2020, subject to customary closing conditions. aTyr has also granted the underwrit

• 

  Clinical Catch-Up: December 9-13

  12/16/2019

  It was a particularly busy week in clinical trial news, largely because of the American Society of Hematology Annual Meeting. Here’s a look.

• aTyr Pharma Announces Positive Interim Safety Results from Ongoing Phase 1b/2a Clinical Trial of ATYR1923

  12/12/2019

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced the results of a pre-planned, blinded interim analysis of safety and tolerability, the primary endpoint of its ongoing Phase 1b/2a clinical trial of its lead therapeutic candidate, ATYR1923, in patients with pulmonary sarcoidosis.

• aTyr Pharma Announces Third Quarter 2019 Results and Provides Corporate Update

  11/14/2019

  Interim safety results from Phase 1b/2a proof-of-concept trial of ATYR1923 in pulmonary sarcoidosis patients due in December 2019

• aTyr Pharma to Present at the Stifel Healthcare Conference 2019

  11/13/2019

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Dr. Sanjay Shukla, President and Chief Executive Officer of aTyr, will be presenting at the Stifel Healthcare Conference 2019, which is being held November 19-20 in New York.

• aTyr Pharma to Announce Third Quarter Results on November 14thManagement to host conference call and webcast at 5:00 pm EST / 2:00 pm PST

  11/7/2019

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report third quarter 2019 results after the market close on Thursday, November 14, 2019.